目的 分析非布司他治療慢性腎病伴高尿酸血癥的療效和機(jī)制。方法 回顧2015年10月-2017年10月到河南醫(yī)學(xué)高等?？茖W(xué)校附屬醫(yī)院診治的慢性腎病伴高尿酸血癥的患者共108例，按照隨機(jī)原則分為兩組，觀察組54例患者采用非布司他治療，對(duì)照組54例患者采用別嘌醇治療，療程均為24周。檢測兩組患者治療前后血尿酸（UA）、血肌酐（Scr）、腎小球?yàn)V過率估算值（eGFR）、血尿素氮（BUN）、血白蛋白（Alb）和尿微量蛋白尿（u-mAlb）水平，比較兩組患者療效，記錄肝功能受損、皮疹、胃腸道反應(yīng)和血脂升高等不良反應(yīng)發(fā)生情況。結(jié)果 治療前兩組患者各項(xiàng)指標(biāo)無明顯差異；治療后UA、Scr、BUN、u-mAlb、eGFR均較治療前明顯降低，Alb較治療前明顯升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后觀察組患者UA、Scr、BUN和u-mAlb明顯低于對(duì)照組，eGFR和Alb明顯高于對(duì)照組，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組患者高尿酸血癥治療總有效率為77.78%，明顯高于對(duì)照組患者的55.56%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；觀察組患者腎功能治療總有效率為83.33%，明顯高于對(duì)照組患者的62.96%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組肝功能受損、皮疹、胃腸道反應(yīng)和血脂升高等不良反應(yīng)發(fā)生率明顯低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 非布司他治療慢性腎病伴高尿酸血癥療效確切，能夠有效降低血尿酸水平，保護(hù)患者腎功能，不良反應(yīng)發(fā)生率低，建議臨床推廣應(yīng)用。

Objective To analyze the efficacy and mechanism of febuxostat in treatment of chronic kidney disease accompanied with hyperuricemia.Methods A total of 108 patients diagnosed with chronic kidney disease accompanied with hyperuricemia in our hospital from October 2015 to October 2017 were involved in this research.They were randomly divided into two groups.54 patients in observation group were treated with febuxostat,and 54 patients in control group were treated with allopurinol.Efficacy was compared in two groups.Results Indexes in two groups before treatment showed no obvious difference.After treatment,levels of blood uric acid,serum creatinine,blood urea nitrogen and urinary microalbuminuria in observation group were significantly lower than those in control group,and estimated value of glomerular filtration rate and blood albumin were obviously higher compared to control group (P< 0.05).Total effective rates of hyperuricemia and renal function in observation group were significantly higher than those in control group,and adverse reaction incidence of liver function damage,erythra,gastrointestinal reaction and blood lipid increase was obviously lower compared to control group (P< 0.05).Conclusion The efficacy of febuxostat in treatment of chronic kidney disease accompanied with hyperuricemia is remarkable,which can effectively reduce blood uric acid level,protect renal function of patients and lower adverse reaction incidence,and recommend clinical popularization and application.